A “shopping war” for Medivation?

It appears that the major pharma companies have initiated yet another merger frenzy, with at least two companies expressing interest in acquiring Medivation (the company that developed enzalutamide/Xtandi).

Whether this is really of any great significance to the average patient with progressive prostate cancer in the short term is open to question. Medivation seems to be trying hard to avoid being acquired, but both Sanofi and Pfizer are now known to have shown a very clear interest in acquiring Medivation — for a lot of money. And then there is the question of whether Astellas (with whom Medivation is partnered in marketing enzalutamide) might want to get involved.

In addition to enzalutamide, which is currently being tested in the treatment of men with non-metastatic forms of prostate cancer. Medivation also has a so-called PARP inhibitor in development (which may have value in the treatment of BRCA 1/2-positive forms of prostate cancer).

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: